Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of 4% Nebulized Lignocaine vs. 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Willing for flexible bronchoscopy procedure a~Exclusion Criteria:~* Requirement of intravenous sedation to undergo any procedure including EBUS-TBNA, conventional TBNA, radial EBUS procedure and interventional pulmonary procedures~* Sensitivity to lignocaine~* Hemodynamically unstable patients (SBP \< 90 mm Hg)~* Baseline hypoxemia (SpO2 \<92% on room air)~* Pregnancy~* Comorbid illness such as heart failure, CKD, chronic liver disease and others~* Failure to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nebulized lignocaine (Type: EXPERIMENTAL): 2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
- Lignocaine spray (Type: EXPERIMENTAL): 10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
- Combined spray and nebulization (Type: ACTIVE_COMPARATOR): Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).